4502.T
Takeda Pharmaceutical Company Limited
プライム · 医薬品 · 医薬品 · JP
JPY 5,908.00
+1.44%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4505.7B | 4505.7B | 4581.6B | 4263.8B | 4027.5B |
| Cost of Revenue | 384.7B | 1571.6B | 1580.2B | 1426.7B | 1244.1B |
| Gross Profit | 722.0B | 2934.1B | 3001.3B | 2837.1B | 2783.4B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 255.9B | 1084.2B | 1104.8B | 1053.8B | 997.3B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 255.9B | 1084.2B | 1104.8B | 1053.8B | 997.3B |
| Cost and Expenses | 4097.0B | 4499.5B | 4239.0B | 4049.7B | 3537.0B |
| Operating Income (EBIT) | 408.8B | 6.2B | 342.6B | 214.1B | 490.5B |
| Non-Operating | |||||
| Interest Income | 73.8B | 211.2B | 46.5B | 52.1B | 62.9B |
| Interest Expense | 107.2B | 357.6B | 210.1B | 219.8B | 169.7B |
| Net Interest Income | (33.4B) | (146.4B) | (163.5B) | (167.8B) | (106.8B) |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 150.6B | (142.4B) | 175.1B | 52.8B | 375.1B |
| Income Tax Expense | 26.4B | 9.8B | 66.9B | (91.4B) | 58.1B |
| Bottom Line | |||||
| Net Income | 191.8B | (152.4B) | 107.9B | 144.1B | 317.0B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 192.0B | (152.1B) | 108.1B | 144.2B | 317.0B |
| Per Share | |||||
| Basic EPS | ¥122 | (¥97) | ¥68 | ¥92 | ¥204 |
| Diluted EPS | ¥122 | (¥97) | ¥67 | ¥91 | ¥202 |
| Revenue Per Share | ¥2,861 | ¥2,861 | ¥2,902 | ¥2,725 | ¥2,595 |
| Shares | |||||
| Basic Shares Outstanding | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 366.2B | 727.3B | 1104.0B | 942.1B | 1154.9B |
| D&A | 181.6B | 721.1B | 761.4B | 728.0B | 664.4B |
| EBIT | 408.8B | 6.2B | 342.6B | 214.1B | 490.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026